Post-merger Q32 Bio plans Phase 2 trial of promising therapy ADX-097
A Phase 2 clinical trial testing Q32 Bio’s ADX-097 in people with ANCA-associated vasculitis (AAV) will be the result of a recently announced merger between the company and Homology Medicines. While further details on the trial were not disclosed, results are expected in the second half of…